Doug Hampton

Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1

by

New AOC 1001 data demonstrate improvement in additional functional measures including hand grip, muscle strength and patient reported outcomes, augmenting previously reported positive data showing improvements in myotonia, muscle strength and mobility   New long-term safety data of AOC 1001 continue to demonstrate favorable safety and tolerability with over 200 infusions totaling 46.2 patient-years of … Read more

Arkadia Festival 2023 Fast Approaching–Daily Schedules Announcing October 6

by

LAS VEGAS, Oct. 6, 2023 /PRNewswire/ — Promising an immersive and uniquely transformative experience, Fit For Service’s ARKADIA: Festival Of A More Beautiful World returns to the mind-bending venue of AREA15 on November 2–5, 2023. The festival lineup features an extraordinary roster of talented artists, visionary speakers, and inspiring workshops, curated to kindle the imagination and … Read more

Cano Health Files Preliminary Proxy Statement with the SEC to initiate plan for Reverse Stock Split

by

MIAMI, Oct. 5, 2023 /PRNewswire/ — Cano Health, Inc. (“Cano Health” or the “Company“) (NYSE: CANO) today announced that it has filed a preliminary proxy statement with the SEC regarding a special stockholders’ meeting to authorize Cano Health’s Board of Directors to effect a reverse stock split of the Company’s Class A and Class B common … Read more

US-AMERIKANISCHE FDA ERTEILT LIPOGEMS® ZWEITE IDE-ZULASSUNG FÜR EINE KLINISCHE STUDIE ZUR BEHANDLUNG VON KNIE-OSTEOARTHRITIS

by

ATLANTA, 5. Okt. 2023 /PRNewswire/ — Die US Food and Drug Administration (FDA) hat Lipogems eine weitere IDE-Studie (Investigational Device Exemption) für die Verwendung von Mikrofett zur Behandlung von Knie-Osteoarthritis (OA) erteilt. Die zweite IDE-Studie wird die Sicherheit und Wirksamkeit bei der Behandlung von Knie-OA im Vergleich zur Behandlung mit Kochsalzlösung untersuchen und 15-20 angesehene akademische … Read more

Light Therapy Market to grow by USD 246.87 million from 2022 to 2027 | North America to account for 43% of market growth

by

NEW YORK, Oct. 4, 2023 /PRNewswire/ — The light therapy market is expected to grow by USD 246.87 million from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 4.72% during the forecast period, according to Technavio Research. The market has been segmented by end-user (commercial, domestic, and healthcare), type … Read more

Firmament Facilitates Merger of Prime Providers and Right Choice In-Home Care

by

NEW YORK, Oct. 3, 2023 /PRNewswire/ — Firmament, a provider of structured equity and debt capital solutions to small- and medium-sized enterprises, announced today an investment in Prime Providers (“Prime” or the “Company”), to support the Company’s acquisition of Right Choice In-Home Care (“Right Choice”). Prime is a home-based healthcare organization providing private duty nursing, … Read more

Vela Diagnostics colabora con SRL Inc. para la distribución de productos en Japón

by

FAIRFIELD, N.J., 2 de octubre de 2023 /PRNewswire/ — Vela Diagnostics anunció hoy una colaboración de investigación con SRL Inc, una importante empresa japonesa de servicios de atención médica. Esta asociación tiene como objetivo facilitar la distribución de las soluciones de diagnóstico molecular de vanguardia de Vela Diagnostics en Japón. Establecida en 1970, SRL Inc … Read more

Leo Cancer Care et THERYQ collaborent sur le positionnement patient innovant du système FLASHDEEP

by

PEYNIER, France, 1er octobre 2023 /PRNewswire/ — La collaboration entre Leo Cancer Care et THERYQ réunit la vaste expertise des deux organisations pour créer une solution intégrée qui promet de révolutionner le traitement des tumeurs solides profondes. S’appuyant sur une technologie de pointe et une ingénierie de précision, cette collaboration vise à fournir aux radio-oncologues et … Read more

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

by

SHENZHEN, China, Sept. 30, 2023 /PRNewswire/ — The 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) is set to take place from October 2nd to 6th, 2023, in Hamburg, Germany. Making its debut at this prestigious event, Shenzhen Sibionics Technology Co., Ltd. (hereinafter referred to as “SIBIONICS”) will unveil its flagship … Read more

Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium

by

TAIPEI, Taiwan, Sept. 30, 2023 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will present the clinical design of the FP-045 Phase 1/2 clinical Fanconi anemia clinical study (FuschiA study) currently being initiated, at the Fanconi Anemia Research Fund (FARF) 2023 Scientific Symposium taking place in Vancouver, BC, Canada from September … Read more